Name: 3,6,9,12,15,18,21,24,27,30-Decaoxahentriacontanoic acid
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Purity

95%

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere.

IUPACName

2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]acetic acid

Synonyms

3,6,9,12,15,18,21,24,27,30-DECAOXAHENTRIACONTANOICACID; 405518-55-0; 2,5,8,11,14,17,20,23,26,29-Decaoxahentriacontan-31-oicacid; SCHEMBL3541625; CTK1D4871; XVVLEAQJQOTYFV-UHFFFAOYSA-N

Boiling Point

557.372°C at 760 mmHg

Density

1.122

InChI Key

XVVLEAQJQOTYFV-UHFFFAOYSA-N

InChI

InChI=1S/C21H42O12/c1-24-2-3-25-4-5-26-6-7-27-8-9-28-10-11-29-12-13-30-14-15-31-16-17-32-18-19-33-20-21(22)23/h2-20H2,1H3,(H,22,23)

SMILES

COCCOCCOCCOCCOCCOCCOCCOCCOCCOCC(=O)O

1.Guided bone regeneration in osteoporotic conditions following treatment with zoledronic acid.

Mardas N1, Busetti J2, de Figueiredo JA3, Mezzomo LA4, Scarparo RK5, Donos N6. Clin Oral Implants Res. 2016 Feb 26. doi: 10.1111/clr.12810. [Epub ahead of print]

OBJECTIVES: To evaluate new bone formation in calvarial critical size defects (CSD) under dense polytetrafluoroethylene (d-PTFE), microporous membranes for guided bone regeneration (GBR) in healthy, osteoporotic and osteoporotic treated with zoledronic acid (ZA) rats.

2.Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study).

Dhir V1, Sandhu A2, Kaur J3, Pinto B4, Kumar P5, Kaur P6, Gupta N7, Sood A8, Sharma A9, Sharma S10. Arthritis Res Ther. 2015 Jun 11;17:156. doi: 10.1186/s13075-015-0668-4.

INTRODUCTION: There is reasonable evidence that folic acid 5-10 mg per week leads to reduction in methotrexate (MTX) toxicity in rheumatoid arthritis (RA). However, this is based on studies conducted with lower MTX dosage than used currently. It is unclear whether higher doses of folic acid may be better in reducing toxicity.

3.[Chemical constituents from lipophilic parts in roots of Angelica dahurica var. formosana cv. Chuanbaizhi].

Deng GG, Yang XW, Zhang YB, Xu W, Wei W, Chen TL. Zhongguo Zhong Yao Za Zhi. 2015 Jun;40(11):2148-56.

The chemical constituents from lipophilic parts in the roots of Angelica dahurica var. formosana cv. Chuanbaizhi were studied in this paper. The compounds were separated and purified by repeated column chromatographic methods on silica gel and HPLC, and the chemical structures of compounds were determined by spectral data analyses. Twenty-nine compounds were obtained and identified as isoimperatorin (1), β-sitosterol (2), imperatorin (3), bergapten (4), osthenol (5), xanthotoxin (6), isoimpinellin (7), dehydrogeijerin (8), phellopterin (9), isodemethylfuropinarine (10), 7-demethylsuberosin (11), alloimperatorin (12), xanthotoxol (13), isooxypeucedanin (14), alloisoimperatorin (15), demethylfuropinarine (16), 5-hydroxy-8-methoxypsoralen (17), oxypeucedanin methanolate (18), pabulenol (19), byakangelicin (20), marmesin (21), (+) -decursinol (22), heraclenol (23), oxypeucedanin hydrate (24), marmesinin (25), ulopterol (26), erythro-guaiacylglycerol-β-ferulic acid ether (27), threo-guaiacylglycerol-β-ferulic acid ether (28), and uracil (29).

4.Traditional and non-traditional risk factors for incident peripheral arterial disease among patients with chronic kidney disease.

Chen J1, Mohler ER2, Xie D3, Shlipak M4, Townsend RR2, Appel LJ5, Ojo A6, Schreiber M7, Nessel L3, Zhang X3, Raj D8, Strauss L9, Lora CM10, Rahman M9, Hamm LL11, He J1; CRIC Study Investigators. Nephrol Dial Transplant. 2015 Dec 18. pii: gfv418. [Epub ahead of print]

BACKGROUND: The risk of peripheral arterial disease (PAD) is higher in patients with chronic kidney disease (CKD) compared with those without. However, reasons for this increased risk are not fully understood.

3,6,9,12,15,18,21,24,27,30-Decaoxahentriacontanoic acid, provides a long, flexible polyether scaffold terminating in a carboxylic acid for efficient conjugation to targeting and E3 ligase-binding modules. Its ether-rich chain supports solubility and conformational adaptability, which can help tune linker length and presentation of functional groups in targeted protein degradation workflows. The detailed structural and synthetic considerations are provided below.

Structure: The linker is a polyether carboxylic acid featuring a repeating ethylene-oxide motif that imparts high flexibility and polarity. It contains multiple ether linkages along an extended aliphatic backbone and a terminal carboxyl group suitable for amide or ester formation.

Reactivity: The carboxylic acid enables standard PROTAC assembly via activation to form amide bonds with amine-bearing ligands or via ester intermediates for subsequent transformations. Common approaches include carbodiimide-mediated coupling, often paired with coupling additives, using polar aprotic solvents under conditions that minimize side reactions. Mechanistically, activation of the acid generates a reactive ester-like intermediate that undergoes nucleophilic attack by the partner amine to yield stable amide-linked constructs.

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂